G. Tatsis et al., CLINICAL AND MICROBIOLOGICAL EVALUATION OF PEFLOXACIN IN LOWER RESPIRATORY-TRACT INFECTIONS, Journal of international medical research, 24(6), 1996, pp. 478-481
Citations number
9
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
Patients with Gram-negative lower respiratory tract infections (acute
exacerbation of chronic bronchitis (n = 23), pneumonia (n = 4), and br
onchiectasis (n = 5) were treated with pefloxacin, 400 mg twice daily,
given either intravenously or orally. Symptoms, signs and sputum volu
me and colour were monitored daily, Chest X-rays, sputum culture and G
ram-stain examinations were carried out on days 1 and 5, and immediate
ly alter the end of the treatment. There was a clinical improvement, a
s indicated by the incidence of cough, dyspnoea and rales, and by sput
um volume and colour in 31 patients (97%). Microbiological improvement
. as indicated by the complete elimination of sputum pathogens and pus
cells, was achieved in 28 of the patients (88%), In one patient, an a
dverse effect, renal failure, occurred. These results suggest that pef
loxacin is both clinically and microbiologically effective for the tre
atment of Gram-negative lower respiratory tract infections.